Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells

Inclusion Criteria:

1.Understanding the whole process of the study, voluntary participation and signed theinformed consent; 2.18 Years to 65 Years old, Body Mass Index (BMI) between 18.5-35; 3.Diagnosed according to biopsy for Psoriasis vulgaris for more than 6 months andresistance to phototherapy, systemic therapy, or a combination of these therapies,BSA(bodysurface area)>10%, PGA≥3 and PASI>10 at baseline; 4. Patients participated in any stem celltherapy within 6 months;

Exclusion Criteria:

1. WBC(white blood cell count ) <3.5x109/L, blood platelet count<100x109/L,hemoglobin<100g/L serum creatinine>1.5 x ULN(upper limit of normal), bilirubin > 1.5 xULN(upper limit of normal), AST(SGOT,glutamic-oxalacetictransaminase)/ALT(SGPT,glutamic-pyruvic transaminase) >2.0 x ULN(upper limit ofnormal);Either HIV-antibody(human immunodeficiency virus-antibody), HBV-antibody (hepatitis B virus-antibody ) or syphilis antibody is positive;

2. Have a serious heart, lung, kidney and other vital organs and endocrine system lesionsand the history,Patients suffering from any acute or chronic infectious diseases,patients suffering from malignant tumor; Mental disorders, history of alcohol abuse,drug or other substance abuse;

3. Patients who have received systemic therapy within recent one month or topical therapyin two weeks;

4. Having a serious allergic history or being allergic to two or more than 2 kinds offood or drugs;

5. Pregnant women, or women who ready for pregnancy or lactating; Patients participatedin any clinical trials within 3 months; Other cases which researchers believe that cannot enroll.